Italian study reviews Real-World use of targeted leukemia drug
NCT ID NCT03898128
First seen Jan 04, 2026 · Last updated May 18, 2026 · Updated 23 times
Summary
This study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials in Italy. The goal was to learn more about the drug's side effects, how well it worked, and its costs in everyday hospital use. No new treatments were given; the study simply gathered existing information to improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AUSL Romagna
Ravenna, RA, 48121, Italy
-
Azienda ULSS2 Marca Trevigiana
Treviso, TV, 31100, Italy
-
Irst Irccs
Meldola (FC), FC, 47014, Italy
-
Ospedale S. Eugenio
Roma, 00144, Italy
-
ULSS 3 Serenissima
Mestre, Venezia, 30174, Italy
Conditions
Explore the condition pages connected to this study.